Clinical Trial Update: The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating the efficacy, mechanism, and safety of a combination therapy consisting of a sodium-glucose co-transporter-2 (SGLT2) inhibitor and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• GLP-1 receptor agonist
• SGLT2 inhibitor

Snippet

Sponsor: University Health Network, Toronto | Conditions: Kidney Transplant Recipients | Phase 2 | Status: RECRUITING